Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress GlobeNewswire November 10, 2025 DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $280.7 million cash, cash equivalents […]